Evidence map›Paper›PMID 33221858›Full record

ArticleThe Journal of clinical endocrinology and metabolism2021

USP8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors.

Andrew V Uzilov, Patricia Taik, Khadeen C Cheesman, Pedram Javanmard, Kai Ying, Alessia Roehnelt, Huan Wang, Marc Y Fink, Chun Yee Lau, Aye S Moe and 9 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Cushing syndrome.Nature reviews. Disease primers · 2025
    Review
  11. Grading and staging for pituitary neuroendocrine tumors.Brain pathology (Zurich, Switzerland) · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.The Journal of clinical endocrinology and metabolism · 2023
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Andrew V UzilovDepartment of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York.
Patricia TaikSema4, Stamford, Connecticut.
Khadeen C CheesmanDivision of Endocrinology, Diabetes, and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Pedram JavanmardDivision of Endocrinology, Diabetes, and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Kai YingSema4, Stamford, Connecticut.
Alessia RoehneltDivision of Endocrinology, Diabetes, and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Huan WangSema4, Stamford, Connecticut.
Marc Y FinkDepartment of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York.
Chun Yee LauDepartment of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York.
Aye S MoeSema4, Stamford, Connecticut.
Joaquin VillarSema4, Stamford, Connecticut.
Joshua B BedersonDepartment of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York.
Andrew F StewartDiabetes, Obesity, and Metabolism Institute and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Michael J DonovanDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.
Milind MahajanDepartment of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York.
Robert SebraDepartment of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York.
Kalmon D PostDepartment of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York.
Rong ChenDepartment of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York.
Eliza B GeerMultidisciplinary Pituitary and Skull Base Tumor Center, Departments of Medicine and Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Sema4 (United States) · USIcahn School of Medicine at Mount Sinai · USMemorial Sloan Kettering Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextPituitary corticotroph adenomas are rare tumors that can be associated with excess adrenocorticotropin (ACTH) and adrenal cortisol production, resulting in the clinically debilitating endocrine condition Cushing disease. A subset of corticotroph tumors behave aggressively, and genomic drivers behind the development of these tumors are largely unknown.

objectiveTo investigate genomic drivers of corticotroph tumors at risk for aggressive behavior.

designWhole-exome sequencing of patient-matched corticotroph tumor and normal deoxyribonucleic acid (DNA) from a patient cohort enriched for tumors at risk for aggressive behavior.

settingTertiary care center. PATIENTS: Twenty-seven corticotroph tumors from 22 patients were analyzed. Twelve tumors were macroadenomas, of which 6 were silent ACTH tumors, 2 were Crooke's cell tumors, and 1 was a corticotroph carcinoma.

interventionWhole-exome sequencing.

main outcome measureSomatic mutation genomic biomarkers.

resultsWe found recurrent somatic mutations in USP8 and TP53 genes, both with higher allelic fractions than other somatic mutations. These mutations were mutually exclusive, with TP53 mutations occurring only in USP8 wildtype (WT) tumors, indicating they may be independent driver genes. USP8-WT tumors were characterized by extensive somatic copy number variation compared with USP8-mutated tumors. Independent of molecular driver status, we found an association between invasiveness, macroadenomas, and aneuploidy.

conclusionsOur data suggest that corticotroph tumors may be categorized into a USP8-mutated, genome-stable subtype versus a USP8-WT, genome-disrupted subtype, the latter of which has a TP53-mutated subtype with high level of chromosome instability. These findings could help identify high risk corticotroph tumors, namely those with widespread CNV, that may need closer monitoring and more aggressive treatment.

Indexed as

DNA Copy Number VariationsACTH-Secreting Pituitary AdenomaAdenomaAdolescentAdultCase-Control StudiesCell Transformation, NeoplasticCohort StudiesEndopeptidasesEndosomal Sorting Complexes Required for TransportExome SequencingFemaleGene FrequencyGenetic Association StudiesGenetic Predisposition to DiseaseHumansEndopeptidasesEndosomal Sorting Complexes Required for TransportTP53 protein, humanTumor Suppressor Protein p53Ubiquitin ThiolesteraseUSP8 protein, humanCNVcorticotroph adenomasCushing diseasegenomicsTP53USP8

Identifiers

PMID33221858
OpenAlexW3109135371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.